Authors

Year

Paper Title

keywords

Mingyue Yao, et al.

2025

IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response

Acute myeloid leukemia, HDAC inhibitor, FLT3-ITD mutation, DNA damage response, Synergistic effect, Drug resistance

Seok Min Kim, et al.

2025

Developing CAR-T/NK cells that target EphA2 for non-small cell lung cancer treatment

cell therapy, chimeric antigen receptor (CAR), CAR-T cell, CAR-NK cell, erythropoietinproducing hepatocellular carcinoma A2 (EphA2), non-small cell lung cancer (NSCLC)

Yuma Fukutani, et al.

2025

Human iPSC-derived NK cells armed with CCL19, CCR2B, high-affinity CD16, IL-15, and NKG2D complex enhance anti-solid tumor activity

Human induced pluripotent stem cell, Gene engineering, Natural killer cell, Solid tumor, Immunotherapy, Off-the-shelf product

Kun Huang, et al.

2025

Epstein-Barr virus mRNA vaccine synergizes with NK cells to enhance nasopharyngeal carcinoma eradication in humanized mice

MT: Regular Issue, Epstein-Barr virus, nasopharyngeal carcinoma, epitopes, mRNA vaccine, natural killer cells, combined therapy, humanized mouse model

Haojing Zang, et al.

2025

PD-1IR2 promotes tumor evasion via deregulating CD8+ T cell function

PDCD1, PD-1^IR2, PBMC-NOG, CD8⁺ T cell, GzmB , IFN-γ

Wenze Wan, et al.

2025

The DCDC2/ENO1 axis promotes tumor progression and immune evasion in intrahepatic
cholangiocarcinoma via activating FGL1‑LAG3 checkpoint

Intrahepatic Cholangiocarcinoma, Tumor-associated antigen, Progression, Immune evasion, Doublecortin domain containing 2, Enolase 1, Fibrinogen-like protein 1

Fan Wang, et al.

2025

A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer

TNBC, ROR1, T cell engager, Immunotherapy

Thomas Leeuw, et al.

2025

Combined TNF-a and OX40L targeting as a new treatment option for hidradenitis suppurativa

TNF-a, OX40L, OX40, hidradenitis suppurativa, Nanobody, xenograft graft-versus-host disease, T cell–dependent
antibody response, delayed-type hypersensitivity skin reaction

Yuanliang Yan, et al.

2025

Sorafenib-loaded metal-organic framework nanoparticles for anti-hepatocellular carcinoma effects through synergistically potentiating ferroptosis and remodeling tumor immune microenvironment

Sorafenib (Sor), hepatocellular carcinoma (HCC), Sor@Fe-MOF nanoparticles (NPs), ferroptotic cell death, CD8⁺ T lymphocytes

Lishu Zhao, et al.

2025

Unraveling tumoral heterogeneity and angiogenesis-associated mechanisms of PD-1 and LAG-3 dual inhibition in lung cancers by single-cell RNA sequencing

PD-1, LAG-3, PDX, squamous cell carcinoma (SCC)

Lijuan Xia, et al.

2025

Repeat-dose toxicity of human umbilical cord mesenchymal stem cells via subcutaneous injection in NOG mice

human umbilical cord mesenchymal stem cells, subcutaneous injection, toxicity
assessment, NOG mice, foamy cells

Hikaru Hayashi, et al.

2025

Synthetic short mRNA prevents metastasis via innate-adaptive immunity

ZC3H12D-s-mRNA complex, natural killer cells, cytotoxic T lymphocytes, lung metastasis

Qiuling Ma, et al.

2025

A bi‑specific CAR‑T cell therapy targeting CD19 and CD22 in relapsed
or refractory B‑ALL

Chimeric antigen receptor T cells · R/r B-ALL · Bi-specific CAR · CD19 · CD22

Meiying Shen, et al.

2025

Therapeutic potential of T-cell receptor targeting the HLA-A*11:01-restricted KRASG12V neoantigen without crossrecognition of the self-antigen RAB7B in solid tumors

KRAS^G12V, neoantigen, peptide, TCR-T

Abdelhadi Boulifa, et al.

2025

Chimeric Antigen Receptor (CAR)-NK92 cells effective against glioblastoma, breastand pancreatic cancer in vitro and in a murine xenograft model of ovarian cancer

Glioblastoma, Breast cancer, Pancreatic cancer, Ovarian cancer, CD44v6, CAR-NK, 3D tumor models, NK92 cell line, Immunotherapy

Xiaobing Wang, et al.

2025

An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis

iPSC-derived CAR-NK, CD19/BCMA dual-targeting, Systemic sclerosis, B cell depletion, Autoimmune diseases, Tissue regeneration

Linqin Wang, et al.

2025

CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells

CD70, induced pluripotent stem cell, multiplex gene editing, natural killer cell, chimeric antigen receptor, allogeneic rejection

Chaeyeon Kim, et al.

2025

Preclinical investigation of anti‑tumor efficacy of allogeneic natural killer cells combined with cetuximab for head and neck squamous cell carcinoma

Head and neck squamous cell carcinoma · Allogeneic natural killer cell · Cetuximab · Antibody-dependent
cellular cytotoxicity

WENZHUO YANG, et al.

2025

Exploring the correlation and mechanism of natural killer cell cytotoxic sensitivity against gastric cancer

Umbilical cord blood natural killer (UCB-NK) cells; Oxaliplatin; Gastric cancer; Natural killer group 2 member D (NKG2D) ligand (NKG2DL); CD56 (neural cell adhesion molecule NCAM)

Hikaru Hayashi, et al.

2025

Synthetic short mRNA prevents metastasis via innate-adaptive immunity

ZC3H12D-s-mRNA，natural killer cells，cytotoxic T lymphocytes，metastasis，

Nathan Gomes, et al.

2025

Sensitivity to an inhibitor of translation elongation in solid and hematologic cancers

Protein synthesis, Translation, Elongation factor 2, AML, Myeloma, Colorectal cancer

Chuyuan Chen, et al.

2025

Tumor-specific AAV delivery of interleukin-12 enhances antitumor immunity and safety in ovarian cancer xenograft mouse model

Regular Issue, cell specific AAV, interleukin-12, tumor microenvironment, solid tumor, gene therapy, cancer immunotherapy, cytokine

Takashi Tamura, et al.

2024

Study on the Extrapolability of Current Tumorgenicity Test With Mice by Comparing the Syngeneic or Allogeneic Mouse Transplantation Model

extrapolability, tumorigenicity test, syngeneic transplantation, allogeneic transplantation, NOG mouse, induced pluripotent stem cell

Peihong Wang, et al.

2024

Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib

FLT3-ITD mutations， FLT3 kinase inhibitors， resistance，AML

Tetsuro Tachi, et al.

2024

Antitumor efects of intracranial injection of B7‑H3‑targeted Car‑T and Car‑Nk cells in a patient‑derived glioblastoma xenograft model

Antitumor efect · CAR-NK cell therapy · Glioblastoma (GBM) · B7-H3

Hami Ashraf, et al.

2024

Clinicopathologic Effects of Xenogeneic GvHD Induced by Adoptively Transferred Human-Derived T Cells in Severely Immunodeficient Mice

Adoptive immunotherapy, Evaluation, Graft, Host disease, Immunodeficient mice, Preclinical drug, Xenotransplantation

Rong A, et al.

2024

Respiratory delivery of single low-dose nebulized PFCE-C25 NEs for lymphatic transport and durable stimulation of antitumor immunity in lung cancer

PFCE-C25 nanoemulsions (NEs), LAG-3，lung cancer，huPBMC-NOG

Markus Kellner, et al.

2024

The Nuclear Speckles Protein SRRM2 Is Exposed on the Surface of Cancer Cells

SRRM2, target identification, cancer target, therapeutic antibodies

Iga Jancewicz, et al.

2024

New CEACAM‑targeting 2A3 single‑domain antibody‑based chimeric
antigen receptor T‑cells produce anticancer effects in vitro and in vivo

Nanobodies · Cancer microenvironment · Immune checkpoints · Cancer biomarker · CEACAM5/6 · CART-cells

Yueyu Dai, et al.

2024

Afatinib boosts CAR-T cell antitumor therapeutic efficacy via metabolism and fate reprogramming

afatinib (AFA), PI3K, CAR-T, ROS,

Yuna Jo, et al.

2024

Targeting ROS-sensing Nrf2 potentiates anti-tumor immunity of intratumoral CD8+ T and CAR-T cells

ROS, Nrf2, CD8⁺ T, CAR-T, myeloid-derived suppressor cells (MDSCs)

Yue Liu, et al.

2024

Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system

CAR-based cellular immunotherapies, Controllable and reversible, Switch, Genetic code expansion system, BOCK

Pamela Leland, et al.

2024

Identification and characterisation of novel CAR-T cells to target IL13Rα2 positive human glioma in vitro and in vivo

CAR-T cell therapy, genetically engineered T cells, IL-13Rα2, immunotherapy, single-chain variable fragment

Min Wu, et al.

2024

Microenvironmental alkalization promotes the therapeutic effects of MSLN-CAR-T cells

methothelin (MSLN), CAR-T, microenvironmental alkalinization, solid cancer, TNBC

Meiou Liu, et al.

2024

MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity

TCR-T, CAR-T, Hybrid MA-TCR-T cell, melanoma

Xing Zhen, et al.

2024

Homology-independent targeted insertion-mediated derivation of M1-biased macrophages harbouring Megf10 and CD3ζ from human pluripotent stem cells

Immunotherapy; Chimeric antigen receptor (CAR)-Modified macrophage; Human pluripotent stem cell (hPSC); Homology-independent targeted insertion (HITI); CD3ζ; Megf10

Daekee Kwon, et al.

2024

Genetically stable multi-gene edited iPSCs-derived NK cells for enhanced cancer immunotherapy

MT: Regular Issue, chimeric antigen receptor, immune rejection, immune checkpoint, induced pluripotent stem cells
multiplex gene editing, Natural killer cells, off-the-shelf

Heliang Wu, et al.

2024

Potential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy

Malignant peritoneal mesothelioma; cell immunotherapy; immunotherapy; intraperitoneal injection; natural killer cells.

Xi Li, et al.

2024

DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors

HER3, Antibody-drug conjugate, Solid tumor therapy, Preclinical

Takeshi Soma, et al.

2024

Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-inhuman interventional study in Japan

human iPSC-derived corneal epithelial cell (iCEPSs), Tumourigenesis, limbal stem-cell deficiency (LSCD), Tumourigenesis, NOG

Lillian K. Skidmore, et al.

2024

Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer

PSMA, ARX517, Prostate Cancer, ADC, PDX, enzalutamide

Yuko Kato, et al.

2024

Engraftment of human mesenchymal stem cells in a severely immunodeficient mouse

Mesenchymal stem cells, Mesenchymal stromal cells, Xenograft model, NOG, Transplantation, Regenerative medicine

Satoshi Kaito, et al.

2024

Inhibition of TOPORS ubiquitin ligase augments the efficacy of DNA hypomethylating agents through DNMT1 stabilization

HMAs, myeloid malignancies, TOPORS, DNMT1,

Stecklum, Maria, et al.

2024

Humanization of NOG mice and next generation NOG mouse strains

Humanized mice，CD34+HSC, CDX, PDX, checkpoint inhibitor

TakashiTamura, et al.

2024

Study on the Extrapolability of Current Tumorgenicity Test With Mice by Comparing the Syngeneic or Allogeneic Mouse Transplantation Model

extrapolability; tumorigenicity test; syngeneic transplantation; allogeneic transplantation; NOG mouse; induced pluripotent stem cell.

Tongcheng Dai, et al.

2024

A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody

Lymphocyte-activation gene 3 (LAG-3), T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT), Bispecific monoclonal antibody, Immune checkpoint inhibitor, Cancer immunotherapy

Norihiro Tsuneyoshi, et al.

2024

Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity

Human iPSC, Gene engineering, Hypoimmunogenic pluripotent cells, HLA-G, PD-L1, PD-L2, Suicide gene

Wentong Jia, et al.

2024

Human CD56+CD39+ dNK cells support fetal survival through controlling trophoblastic cell fate: immune mechanisms of recurrent early pregnancy loss

recurrent pregnancy loss, CD56+CD39+ dNK subset, NOG mice, adoptive transfer, placental trophoblast cell fate, M-CSF

Xuetong Wang, et al.

2024

A splicing isoform of PD-1 promotes tumor progression as a potential immune checkpoint

CD8-positive T cells, T cells, Cancer immunotherapy, Alternative splicing

Carina Metz, et al.

2024

Pharmacokinetic and Environmental Risk Assessment of Prime-2-CoV, a Non-Replicating Orf Virus-Based Vaccine against SARS-CoV-2

 Orf virus, poxvirus, viral vector, vaccine, environmental risk assessment, biodistribution, shedding

Dan Wang, et al.

2024

A preclinical study of allogeneic CD19 chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignancies

allogeneic CD19‐CAR‐DNTs, B‐cell malignancies, cytotoxicity and safety, off‐the‐shelf immunotherapy

Tian Deng, et al.

2024

Rapidly-manufactured CD276 CAR-T cells exhibit enhanced persistence and efcacy in pancreatic cancer

CD276, Chimeric antigen receptor, Rapidly-manufactured CAR-T, Dash CAR-T, Pancreatic cancer

Qinghui Xiong, et al.

2024

The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment

CD70, Chimeric Antigen Receptor T-Cells, Renal Cell Carcinoma, Nanobody

Wenjiao Xia, et al.

2023

ngineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy

breast cancers, cytotherapy, chimeric antigen receptor, NK cells, sPD-1

Klaus-Peter Künkele, et al.

2023

CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy

Vγ9Vδ2 T cell; chimeric antigen receptor(CAR); carcinoembryonic antigen(CEA); graft-versus-host disease(GVHD); off-the-shelf; glucocorticoid-induced TNFR-related protein(GITR); tetrakis-pivaloyloxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1-bisphosphonate(PTA)

S. Momsen Reincke

2023

Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells

 (NMDAR-CAAR) T cells， B cell, Naml6

Kevin H Lin, et al.

2023

P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia

AML, P2RY2-AKT, XPO1

Jie Wang et al.

2022

Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies

CD79b, bispecific, T cell engager, non-hodgkin lymphoma, immunotherapy

Yujeong Her, et al.

2022

Development of humanized patient-derived xenograft models for triple negative breast cancer

Kiyomi Mashima, et al.

2021

Comparison of alemtuzumab, anti-thymocyte globulin, and post-transplant cyclophosphamide for graft-versus-host disease and graft-versus-leukemia in murine
models

graft-versus-leukemia (GVL), graft-versus-host disease (GVHD), huPBMC-NOG, Alemtuzumab, ATG

Takeda, Maki et al.

2021

Elimination of residual undifferentiated induced pluripotent stem cells (iPSCs) using irradiation for safe clinical applications of iPSC-derived cardiomyocytes

human induced pluripotent stem cells; Irradiation; Stem cell therapy; Tumorigenicity.

Yili Chen, et al.

2021

A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy

HER2/PD-L1, BsAbs, ductal carcinoma, gastric carcinoma, PBMCs, humanized

Michael J. Giffin, et al.

2021

AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

BiTE, SCLC, DLL3, PDX, PBMCs, humanized

(VR)Guojuan Miao, et al.

2021

Development of a novel anti-B7-H4 antibody enhances anti-tumor immune response of human T cells

B7-H4, antibody, pan T cell, humanized, combined therapy

Hirotoshi Akane, et al.

2021

Spontaneous granulocytic leukemia in a NOD/Shi-scid IL-2Rγnull mouse

granulocytic leukemia, spontaneous tumor

Yang Gao, et al.

2021

Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine

intrahepatic cholangiocarcinoma, PDX, lenvatinib

Yuji Yamashita, et al.

2021

Data on long-term survival of the NOD/Shi-scid IL-2Rγ null (NOG) mouse in two facilities

survival rate, histopathology, tumorigenicity

Shahrokh Abdolahi, et al.

2021

Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model

NK cell therapy, anti-PD-1 antibody, gastric cancer

Yoichi Shida, et al.

2021

Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors

NK cell therapy, PD-1/PD-L1, glioblastoma

N Ahmadbeigi, et al.

2021

Characterization of a xenograft model for anti-CD19 CAR T cell studies

CAR-T cells, Raji cells, lymphoma, inoculation routes

Ayaka Hara, et al.

2021

CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy

CD1d, iNKT cells, glioblastoma

Sebastian Kollmann, et al.

2021

A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells

HSCs

Xueliang Gao, et al.

2021

Nuclear PFKP promotes CXCR4 dependent T cell acute lymphoblastic leukemia infiltration.

CDX, T cell acute lymphoblastic leukemia (T-ALL), CXCR4

Jianshui Zhang, et al.

2021

Human Microglia Extensively Reconstitute in Humanized-BLT Mice With Human Interleukin-34 Transgene and Support HIV-1 Brain Infection.

Humanized bone marrow-liver-thymic mouse (hu-BLT mouse), macroglia, HIV-1, central nervous system (CNS),

Camilla Bjørnbak Holst, et al.

2021

Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma

glioblastoma, IL-8,ICOS ligand,biomarker, CDX

Malene Bredahl Hansen, et al.

2021

Identification of lysosome-targeting drugs with anti-inflammatory activity as potential invasion inhibitors of treatment resistant HER2 positive cancers.

HER2/ErbB2, CDX, ovarian cancer

Helle Samdal, et al.

2021

Establishment of a Patient-Derived Xenograft Model of Colorectal Cancer in CIEA NOG Mice and Exploring Smartfish Liquid Diet as a Source of Omega-3 Fatty Acids.

PDX, colorectal cancer

Wei Dai, et al.

2021

Activation of transmembrane receptor tyrosine kinase DDR1-STAT3 cascade by extracellular matrix remodeling promotes liver metastatic colonization in uveal melanoma

DDR1, TGF-β, uveal melanoma (UM), CDX, metastasis

Haiqing Ni, et al.

2021

Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody

CD47, CD20, VEGF-A, mAbs, acute myeloid leukemia (AML), PBMCs, humanized

Haiping Jiang, et al.

2021

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

PD-L1, LAG-3, bsAbs, melanoma, PBMCs, humanized, cancer immunotherapy

Qingming Wang, et al.

2021

A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells

chimeric antigen receptor (CAR), B-cell maturation antigen (BCMA), adoptive T-cell therapy (ACT), truncated human EGFR (eEGFR), multiple myeloma (MM), CDX

Yongliang Liu, et al.

2021

CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia

acute myeloid leukemia (AML), CD9, PDX, humanized

Yosuke Nagesawa, et al.

2021

Human osteoclastogenesis in Epstein-Barr virus-induced erosive arthritis in humanized NOD/Shi-scid/IL-2Rγnull mice.

autoimmune,  Epstein-Barr virus, HSCs, humanized

Shoichi Iriguchi, et al.

2020

A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy

CAR-T, iPSC-derived T cell,

Tea Soon Park, et al.

2020

Vascular progenitors generated from tankyrase inhibitor-regulated naïve diabetic human iPSC potentiate efficient revascularization of ischemic retina

Naïve diabetic vascular progenitors (N-DVP), hiPSC,

Daisuke Doi, et al.

2020

Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson’s disease

dopaminergic progenitors (DAPs) , iPSC-derived, Parkinson's disease, safety and efficacy assessment

Saori Igura, et al.

2020

Pathological study of tubular aggregates occurring spontaneously in the skeletal muscles of non-obese diabetic/Cg -Prkdc scid Il2rgt m1sug /ShiJic (NOG) mice

sarcoplasmic reticulum, skeletal muscle, tubular aggregate

Paul Savage, et al.

2020

Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors.

PDX, breast cancer

Elly L van der Veen, et al.

2020

Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs.

melanoma, PD-1, mAb, CDX, HSCs, humanized

Wanlu Cao, et al.

2020

LGR5 marks targetable tumor-initiating cells in mouse liver cancer

LGR5, liver cancer, allograft tumor model

Mari I. Suominen, et al.

2020

A clear increase in TILs and modest tumor growth inhibition by pembrolizumab in prostate cancer tumors growing in bone of CD34+ engrafted NOG mice

prostate cancer bone metastasis, anti-PD-1, HSCs, humanized

Zhihui Kuang, et al.

2020

A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment

PD-L1, OX40, CD134, bsAbs, PBMC, colon cancer, lung cancer, humanized

Linlin Ma, et al.

2020

Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential

CD47/SIRPα, CD20, CD47, bsAbs, lymphoma

Yan Wang, et al.

2020

Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity

CD47, PD-L1, bsAbs, SIRPα

Run Lin, et al.

2020

Fatty Acid Oxidation Controls CD8+ Tissue-Resident Memory T-cell Survival in Gastric Adenocarcinoma

PD-L1, gastric adenocarcinoma,  tissue-resident memory T cells (Trm), PDX, humanized

Kun Zhang, et al.

2020

Nonclinical safety, tolerance and pharmacodynamics evaluation for meplazumab treating chloroquine-resistant Plasmodium falciparum

CD147, safety, toxicology, RBC, Plasmodium falciparum, humanized

Stijn JH Waaijer, et al.

2020

Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.

CD3, glypican 3(GPC3), bsAbs, hepatocellular carcinoma,  ovarian clear cell carcinoma, HSCs, humanized

Angelique Sao-Mai Sy Do, et al.

2020

CD133 mRNA-Loaded Dendritic Cell Vaccination Abrogates Glioma Stem Cell Propagation in Humanized Glioblastoma Mouse Model.

dendritic cell vaccine, CD133, glioblastoma, HSCs, humanized

Shinya Rai, et al.

2020

Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V

acute myeloid leukemia (AML), PDX

Jennifer Y.Ge, et al.

2020

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer

triple-negative breast cancer (TNBC), CDK4/6 inhibitor, BET inhibitor, CDX

Ping He, et al.

2020

Co-expressing LRP6 With Anti-CD19 CAR-T Cells for Improved Therapeutic Effect Against B-ALL

CAR-T cells, T memory cell, B-cell ALL

Elin M. V. Forsberg, et al.

2019

HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy–Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice

melanoma,HER2, CAR-T, ACT,

Walid Warda, et al.

2019

CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor–Engineered T Cells

chronic myeloid leukemia (CML), IL1RAP, CAR-T, HSCs, humanized

Xiaofang Guo, et al.

2019

The Preconditioning of Busulfan Promotes Efficiency of Human CD133+ Cells Engraftment in NOD Shi-SCID IL2Rγcnull (NOG) Mice via Intra-Bone Marrow Injection

CD133+ stem cell, hematopoietic differenciation, humanized

Jie Wang, et al.

2019

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit

PD-1,PBMC, receptor occupancy, humanized

Jing Zhang, et al.

2019

Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma

cyclin-dependent kinase 7/9 (CDK7/9) inhibitor, uveal melanoma (UM), CDX, metastasis

Cedric Darini, et al.

2019

An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy

HER2, PKR, gastric cancer, PDX

Thi Bui, et al.

2018

Enhanced proliferation and effector functions of human immune cells in response to immune checkpoint therapy of MDA-MB-231 tumor bearing huNOG mice engrafted with human CD34+ cells

immune check point therapy, PD-1, CTLA-4, breast cancer, HSCs, humanized

Berglind O.Einasdottir, et al.

2018

A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma

metastatic melanoma, PDX, T cell

Tiina E. Kähkönen, et al.

2018

Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone

breast cancer, HSCs, humanized

Sarah L. Buchan, et al.

2018

Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.

4-1BB, treg cell, PD-1, combined therapy, PBMCs, humanized

Weiling He, et al.

2017

CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer

PBMCs, humanized, gastric cancer, CD155T/TIGIT, anti-PD-1 mAbs

Qing Zhang, et al.

2017

Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice

chimeric antigen receptor (CAR), T cell, lung cancer, melanoma

Masahiko Yasuda, et al.

2017

Incidence of spontaneous lymphomas in non-experimental NOD/Shi-scid, IL-2Rγ null (NOG) mice

thymic lymphoma, spontaneous

R.Ito, et al.

2016

A Novel Xenogeneic Graft-Versus-Host Disease Model for Investigating the Pathological Role of Human CD4+ or CD8+ T Cells Using Immunodeficient NOG Mice

GvHD, CD4+T cell, CD8+T cell, Th17

B.C.Martel, et al.

2015

Human Atopic Dermatitis Skin-derived T Cells can Induce a Reaction in Mouse Keratinocytes in vivo

atopic dermatitis (AD), skin-infiltrating T cells, keratinocytes

A Kitadate, et al.

2015

MicroRNA-16 mediates the regulation of a senescence–apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas

primary cutaneous T-cell lymphoma (CTCL), non-Hodgkin T/NK-cell lymphoma, CDX

Zhu A Wang, et al.

2014

Luminal cells are favored as the cell of origin for prostate cancer.

prostate cancer, luminal cell, basal cell, CDX,

Nicholas Veomatt, et al.

2014

Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein

leukemia,CDX, mAbs

Chie Kato, et al.

2009

Spontaneous thymic lymphomas in the non-obese diabetic/Shi-scid, IL-2Rgnull mouse

spontaneous thymic lymphoma, T cell

M. Ito, et al.

2008

Antigen-Specific Antibody Production of Human B Cells in NOG Mice Reconstituted with the Human Immune System

B cell, IgG antibody, HSC, humanized

Hirotomo Nakata, et al.

2005

Potent Anti-R5 Human Immunodeficiency Virus Type 1 Effects of a CCR5 Antagonist, AK602/ONO4128/GW873140, in a Novel Human Peripheral Blood Mononuclear Cell Nonobese Diabetic-SCID, Interleukin-2 Receptor γ-Chain-Knocked-Out AIDS Mouse Model

HIV,PBMCs

Mamoru Ito, et al.

2002

NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

HSCs, humanized

Yuki Saito, et al.

2002

The in vivo development of human T cells from CD34(+) cells in the murine thymic environment.

HSCs, humanized

Takashi Yahata, et al.

2002

Functional human T lymphocyte development from cord blood CD34+ cells in nonobese diabetic/Shi-scid, IL-2 receptor gamma null mice.

HSCs, humanized

Hiramatsu H, et al.

2002

Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gammacnull mice model